JPS6221765B2 - - Google Patents
Info
- Publication number
- JPS6221765B2 JPS6221765B2 JP51082846A JP8284676A JPS6221765B2 JP S6221765 B2 JPS6221765 B2 JP S6221765B2 JP 51082846 A JP51082846 A JP 51082846A JP 8284676 A JP8284676 A JP 8284676A JP S6221765 B2 JPS6221765 B2 JP S6221765B2
- Authority
- JP
- Japan
- Prior art keywords
- escin
- amorphous
- ray
- solution
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940011399 escin Drugs 0.000 claims description 42
- 229930186222 escin Natural products 0.000 claims description 42
- 238000002441 X-ray diffraction Methods 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 241000157282 Aesculus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000010181 horse chestnut Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002322 anti-exudative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2530953A DE2530953C2 (de) | 1975-07-11 | 1975-07-11 | Verfahren zur Herstellung von röntgenamorphem Aescin, nach diesem Verfahren erhältliches röntgenamorphes Aescin und dieses enthaltende Arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5234915A JPS5234915A (en) | 1977-03-17 |
| JPS6221765B2 true JPS6221765B2 (enExample) | 1987-05-14 |
Family
ID=5951225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51082846A Granted JPS5234915A (en) | 1975-07-11 | 1976-07-12 | Xxray diffraction amorphous escin* its preparation and ittcontaining antitransudation agent |
| JP61304058A Granted JPS6366127A (ja) | 1975-07-11 | 1986-12-22 | Ｘ線回折無定形エスシンを含有する抗滲出剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61304058A Granted JPS6366127A (ja) | 1975-07-11 | 1986-12-22 | Ｘ線回折無定形エスシンを含有する抗滲出剤 |
Country Status (20)
| Country | Link |
|---|---|
| JP (2) | JPS5234915A (enExample) |
| AU (1) | AU510463B2 (enExample) |
| BE (1) | BE844053A (enExample) |
| BG (1) | BG27379A3 (enExample) |
| CA (1) | CA1064903A (enExample) |
| CS (1) | CS208184B2 (enExample) |
| DE (1) | DE2530953C2 (enExample) |
| ES (1) | ES449748A1 (enExample) |
| FI (1) | FI62099C (enExample) |
| FR (1) | FR2316961A1 (enExample) |
| GB (1) | GB1550845A (enExample) |
| HK (1) | HK33681A (enExample) |
| HU (1) | HU174603B (enExample) |
| PH (1) | PH13989A (enExample) |
| PL (1) | PL99028B1 (enExample) |
| PT (1) | PT65302B (enExample) |
| RO (1) | RO70354A (enExample) |
| SU (1) | SU786857A3 (enExample) |
| YU (1) | YU41812B (enExample) |
| ZA (1) | ZA764065B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1252201B (it) * | 1991-12-12 | 1995-06-05 | Dompe Farmaceutici Spa | S-carbossimetilcisteina sale di lisina monoidrato e procedimento per la sua preparazione. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE302543C (enExample) * | ||||
| NL301747A (enExample) * | 1962-12-14 | |||
| YU37063B (en) * | 1971-12-06 | 1984-08-31 | Lek Tovarna Farmacevtskih | Process for preparing x-ray amorphous water-sulubleascin |
| DE2357226A1 (de) * | 1973-11-16 | 1975-05-28 | Merck Patent Gmbh | Verfahren zur herstellung von wasserloeslichem beta-aescin |
-
1975
- 1975-07-11 DE DE2530953A patent/DE2530953C2/de not_active Expired - Lifetime
-
1976
- 1976-06-30 PT PT65302A patent/PT65302B/pt unknown
- 1976-06-30 FI FI761895A patent/FI62099C/fi not_active IP Right Cessation
- 1976-07-05 BG BG033673A patent/BG27379A3/xx unknown
- 1976-07-07 GB GB28233/76A patent/GB1550845A/en not_active Expired
- 1976-07-07 SU SU762377645A patent/SU786857A3/ru active
- 1976-07-08 ZA ZA764065A patent/ZA764065B/xx unknown
- 1976-07-08 YU YU1670/76A patent/YU41812B/xx unknown
- 1976-07-08 AU AU15729/76A patent/AU510463B2/en not_active Expired
- 1976-07-09 CS CS764567A patent/CS208184B2/cs unknown
- 1976-07-09 CA CA256,650A patent/CA1064903A/en not_active Expired
- 1976-07-09 HU HU76MA2797A patent/HU174603B/hu not_active IP Right Cessation
- 1976-07-10 PL PL1976191114A patent/PL99028B1/pl unknown
- 1976-07-10 ES ES449748A patent/ES449748A1/es not_active Expired
- 1976-07-10 RO RO7686932A patent/RO70354A/ro unknown
- 1976-07-12 JP JP51082846A patent/JPS5234915A/ja active Granted
- 1976-07-12 BE BE168849A patent/BE844053A/xx not_active IP Right Cessation
- 1976-07-12 FR FR7621313A patent/FR2316961A1/fr active Granted
- 1976-07-12 PH PH18678A patent/PH13989A/en unknown
-
1981
- 1981-07-16 HK HK336/81A patent/HK33681A/xx unknown
-
1986
- 1986-12-22 JP JP61304058A patent/JPS6366127A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0336808B2 (enExample) | 1991-06-03 |
| BG27379A3 (bg) | 1979-10-12 |
| CS208184B2 (en) | 1981-08-31 |
| GB1550845A (en) | 1979-08-22 |
| FI761895A7 (enExample) | 1977-01-12 |
| AU1572976A (en) | 1978-01-12 |
| PL99028B1 (pl) | 1978-06-30 |
| BE844053A (fr) | 1977-01-12 |
| FR2316961B1 (enExample) | 1984-04-20 |
| FI62099B (fi) | 1982-07-30 |
| YU41812B (en) | 1988-02-29 |
| YU167076A (en) | 1983-06-30 |
| FI62099C (fi) | 1982-11-10 |
| HU174603B (hu) | 1980-02-28 |
| ZA764065B (en) | 1977-07-27 |
| FR2316961A1 (fr) | 1977-02-04 |
| SU786857A3 (ru) | 1980-12-07 |
| JPS6366127A (ja) | 1988-03-24 |
| PT65302B (de) | 1977-12-13 |
| CA1064903A (en) | 1979-10-23 |
| PH13989A (en) | 1980-11-28 |
| DE2530953C3 (de) | 1994-07-07 |
| JPS5234915A (en) | 1977-03-17 |
| DE2530953A1 (de) | 1977-01-27 |
| DE2530953C2 (de) | 1994-07-07 |
| AU510463B2 (en) | 1980-06-26 |
| RO70354A (ro) | 1982-03-24 |
| HK33681A (en) | 1981-07-24 |
| ES449748A1 (es) | 1977-08-16 |
| PT65302A (de) | 1976-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cwiertnia et al. | Stability of diclofenac sodium in the inclusion complex with β-cyclodextrin in the solid state | |
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| IT8224368A1 (it) | Medicamenti ad alto grado di solubilità e procedimento per il loro ottenimento | |
| ME01520B (me) | KRISTAL JEDINJENJA 1,2-DIHIDROPIRIDINA l METOD ZA NJEGOVU PROIZVODNJU | |
| CN110075000A (zh) | 一种羟基酪醇包合物及其制备方法和用途 | |
| JPS6221765B2 (enExample) | ||
| TAKAHASHI et al. | Interaction of several nonsteroidal antiinflammatory drugs with pectin in aqueous solution and in solid state | |
| Portoghese et al. | Relative hydrolytic rates of certain alkyl (b) dl-α-(2-piperidyl)-phenylacetates | |
| NO304730B1 (no) | FremgangsmÕte for fremstilling av nimesulide og cyklodekstrinkomplekser | |
| JPS6327435A (ja) | バイカレイン高含有エキスの抽出法 | |
| Xia et al. | Synthesis and characterization of a novel soluble neohesperidin-copper (II) complex using Ion-exchange resin column | |
| KR950703518A (ko) | 틸리딘 이수소 오르토포스페이트, 그 제조방법 및 이를 함유한 의약 제제(tilidin dihydrogen orthophosphate, method of preparing it and pharmaceutical preparations containingit) | |
| FI71314C (fi) | Foerfarande foer framstaellning av en terapeutiskt anvaendbar beta-(4,5-difenyloxazol-2-yl) propionsyrakalciumsalt | |
| Minzanova et al. | Complexes of pectin polysaccharide with acetylsalicylic acid. | |
| RU95115702A (ru) | Анальгезирующее жаропонижающее лекарственное средство и способ его получения | |
| US5534551A (en) | Aminoguanidine spray drying process | |
| CN110540542A (zh) | 一种苯乙酸类化合物的钠盐、结晶形式及其制备方法 | |
| CN108752334A (zh) | 一种黄藤素-对苯二甲酸药物共晶及其制备方法 | |
| KR820002108B1 (ko) | 수용성 산성 사포닌의 제조 방법 | |
| NO762064L (enExample) | ||
| JPH0348897B2 (enExample) | ||
| JPH05310686A (ja) | Ｓ−カルボキシメチルシステインリジンモノハイドレートおよびその調製方法 | |
| SU501762A1 (ru) | Способ получени препарата низкомолекул рного поливинилпирролидона | |
| Manna et al. | Studies on Erythromycin Melibionate—A New Water Soluble Salt of Ebythrowycin | |
| MXPA00007921A (en) | Novel galenic formulations of meloxicam for oral administration |